Revolutionizing
Treatment for Obstructive Lung Diseases

COPD, Asthma, and cystic fibrosis are life-altering conditions impacting millions globally. We’re committed to transforming the landscape of obstructive lung disease treatment with groundbreaking therapies.

The Future of Obstructive Lung Disease Treatment

Introducing a new class of small peptidomimetic therapies inspired by club cell secretory protein-16 (CC16). This innovative treatment is designed to both treat and prevent obstructive lung diseases like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis by harnessing the power of advanced molecular design.

By mimicking the protective properties of CC16, our peptidomimetic therapy delivers precise, targeted action with exceptional efficacy, charting a path toward a healthier future for those affected by these conditions.

Understanding Obstructive Lung Diseases

Chronic Obstructive Pulmonary Disease

COPD describes a large group of lung diseases, including emphysema and chronic bronchitis, and is the third leading cause of death globally. Despite the severity and rising prevalence of COPD, there is currently no cure. 

Asthma

A chronic respiratory condition characterized by inflammation and narrowing of the airways, which affects approximately 300 million people worldwide. While asthma can be managed with medication, it also lacks a cure, and severe asthma attacks can be life-threatening. 

These conditions underscore the urgent need for innovative and effective treatment options for obstructive lung diseases.

Current Treatment Limitations

The Problem:

At present, no medical treatments are available to modify the natural course of COPD and other obstructive lung diseases. Existing treatments, such as bronchodilators, steroid inhalers, and supplemental oxygen, aim only to alleviate symptoms and reduce the frequency and severity of exacerbations. Still, they do not address the underlying cause of the conditions.

The Facts

CC16 is detectable in the bloodstream, where it can indicate lung health.

Individuals with low blood serum concentrations of CC16 have both reduced lung function growth in childhood and accelerated lung function decline in adult life.

Patients can develop COPD either because their lung function declines faster as adults (i.e. people who smoke), or because they had low lung function since they were children.

Low CC16 levels result in decreased host responses to pathogens, increased inflammation and oxidative stress, and increased airway remodeling—all of which worsen COPD.

Circulating CC16 is reduced in both patient groups, leading to COPD.

In preclinical animal models, administration of CC16 peptidomimetics protects animals from COPD- and asthma-like diseases.

Hear from COPD Patients

See what it’s like for people with chronic lung conditions and why it’s so important we help them get the treatment they deserve.

Our Commitment to Revolutionizing Treatment

Our team is dedicated to revolutionizing treatment for obstructive lung diseases by harnessing the protective power of CC16, a natural lung protein vital for healthy breathing. Our novel therapy aims to offer a new, effective solution for patients suffering from conditions like COPD and asthma.

CONTACT

Get In Touch

Are you an investor, potential partner, or fellow researcher eager to learn more about our groundbreaking work? We invite you to contact our team and explore how we can collaborate to drive innovation forward for patients suffering from obstructive lung diseases.

Contact Us